文献速递泌尿生殖介入MRUS

磁共振引导高强度聚焦超声消融用于前列腺癌局灶治疗——1期试验

Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
PubMed 文献 · Eur Radiol · 2018-04-25

这项经伦理委员会批准的1期前瞻性研究纳入8例低-中危前列腺癌患者(PSA≤10 ng/ml、≤cT2a、Gleason评分≤7(4+3)),在MRI引导下以高强度聚焦超声消融靶组织。共治疗10个靶病灶,平均靶体积2.7 cc、消融后无灌注体积4.3 cc;6个月时所有治疗区MRI均阴性,4/8例患者、6/10个靶病灶(60%)活检无病变,平均PSA由基线5.06降至3.4 ng/ml。作者结论为MRgFUS是非侵入性消融低-中危前列腺癌可行且安全的方法,短期肿瘤学结局可接受。

要点

  • 8例低-中危前列腺癌患者共10个靶病灶接受MRgFUS局灶消融,平均靶体积2.7 cc、消融后无灌注体积4.3 cc。
  • 6个月时所有治疗区MRI均阴性,4/8例患者及6/10个靶病灶(60%)活检无病变。
  • 平均PSA由基线5.06降至6个月时3.4 ng/ml,6/8例患者生活质量参数与基线相似。

核心结论

  • 作者认为MRgFUS是非侵入性消融低-中危前列腺癌可行且安全的方法,短期肿瘤学结局可接受。

研究设计与样本

  • 经伦理委员会批准的1期前瞻性研究,纳入8例PSA≤10 ng/ml、≤cT2a、Gleason评分≤7(4+3)的前列腺癌患者,在MRI引导下以聚焦高强度超声消融靶组织,治疗后6个月以多参数MRI、PSA和经直肠超声活检评估肿瘤学结局。

关键影像表现/征象

  • 8例患者共治疗10个靶病灶,包括6个Gleason 6病灶、2个Gleason 7(3+4)病灶和2个Gleason 7(4+3)病灶。
  • 前列腺体积范围25-50 cc,平均每例患者MRI时间248 min,平均声辐照时间65 min。
  • 平均靶体积2.7 cc,治疗后平均无灌注体积4.3 cc。
  • 6个月时所有治疗区域MRI均阴性。
  • 6/8例患者基线至6个月生活质量参数相似。

诊断标准与关键数值

  • 6个月时活检显示4/8例患者和6/10个靶病灶(60%)无病变。
  • 1例患者治疗部位5针活检中1针见2 mm Gleason 8病变(基线为4+3病变),随后行前列腺切除术且手术切缘阴性。
  • 3例患者见低体积(5-15%)Gleason 6残留病变,接受主动监测。
  • 平均PSA由基线5.06降至6个月时3.4 ng/ml。

临床应用与阅片要点

  • 作者认为MRgFUS是非侵入性消融低-中危前列腺癌可行且安全的方法,短期肿瘤学结局可接受。
  • 要点指出局灶治疗选择性消融局限的、有临床意义的索引病灶并带边缘,同时保留其余腺体和邻近重要结构。
  • 要点指出MRgFUS将MRI与HIFU结合,可实时监测治疗并实现靶向局灶消融。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the feasibility and safety of focal therapy for low-intermediate risk prostate cancer (PCa) with magnetic resonance-guided high frequency focused ultrasound (MRgFUS) METHODS: This IRB-approved phase 1 prospective study enrolled eight patients with prostate specific antigen (PSA) ≤ 10 ng/ml, ≤ cT2a and Gleason score ≤ 7 (4 + 3) disease following informed consent. Under MRI guidance, focused high frequency ultrasound energy was delivered to ablate the target tissue. Treatment-related adverse events were recorded. Oncologic outcomes were evaluated with multiparametric MRI, PSA and TRUS biopsy at 6 months following treatment.

RESULTS: Ten target lesions [six Gleason 6 lesions, two Gleason 7 (3 + 4) and two Gleason 7 (4 + 3)] were treated in eight men (prostate volume range, 25-50 cc; mean MRI time, 248 min per patient; mean sonication duration, 65 min). Mean target volume was 2.7 cc and mean post-treatment non-perfused volume was 4.3 cc. Quality of life parameters were similar between baseline and 6 months in 6/8 patients. All treated regions were negative on MRI; 4/8 patients and 6/10 target lesions (60%) were clear of disease on biopsy. One patient with 2-mm Gleason 8 disease in one of five cores from treatment site (4 + 3 disease at baseline) subsequently underwent prostatectomy with negative surgical margins. Three patients with low volume (5-15%) Gleason 6 residual disease were offered active surveillance. Mean PSA decreased from 5.06 at baseline to 3.4 ng/ml at 6 months.

CONCLUSION: MRgFUS is a feasible and safe method of noninvasively ablating low-intermediate risk PCa with acceptable short-term oncologic outcomes.

KEY POINTS: • Focal therapy selectively ablates locally confined, clinically significant index lesion with a margin while sparing rest of gland and adjacent vital structures. • Magnetic resonance-guided focused high frequency ultrasound surgery (MRgFUS) combines MRI with HIFU. • MRgFUS provides ability to monitor treatments in real time and allows a targeted approach for focal ablation. • MRgFUS is a feasible, safe method of noninvasively ablating low-intermediate risk PCa. • MRgFUS provides acceptable oncologic outcomes at 6 months.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ghai S, Perlis N, Lindner U, et al. Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial. Eur Radiol. 2018. PMID: 29696431. doi:10.1007/s00330-018-5409-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。